Neurotoxin Exposure Treatment Parkinson’s Depression Research Award

Funding Opportunity Number: W81XWH-15-NETPR-DRA
Opportunity Category: Discretionary
Funding Instrument Type: Grant
Category of Funding Activity: Science and Technology and other Research and Development
CFDA Number: 12.420
Eligible Applicants Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility”
Agency Name: DOD-AMRAA
Closing Date: Dec 16, 2015
Award Ceiling:
Expected Number of Awards: 1
Creation Date: Oct 22, 2015
Funding Opportunity Description: Applications to the Fiscal Year 2015 (FY15) Neurotoxin Exposure Treatment Parkinson’s Research (NETPR) program are being solicited by the U.S. Army Medical Research Acquisition Activity (USAMRAA). The executing agent for this Program Announcement/Funding Opportunity is the Congressionally Directed Medical Research Programs (CDMRP). The NETPR was initiated in FY97 to provide support for research of exceptional scientific merit leading to an understanding of the cause, prevention, and treatment of the loss of dopaminergic neurons in the Substantia nigra that result in Parkinson’s disease (PD). The mission of the NETPR Program is to: · Identify surrogate markers of PD, · Correlate distinctive clinical features with specific clusters of these markers, and · Develop interventions in bio-molecular pathways that link markers and expressed clinical features in order to prevent or halt progression of the disease or improve the quality of life for PD patients. Depression is both an epidemiological identified risk factor for development of PD and a co-morbid condition that affects an increasing proportion of individuals as PD progresses. This funding opportunity is specifically focused on the following Areas of Emphasis on depression as a risk factor and/or co-morbidity in PD: · Delineation of metabolic pathways that may lead to identification of molecular markers and/or therapeutic targets associated with modulation or control of serotonergic or non¬serotonergic activity. · Characterization of underlying genetic mechanisms associated with development of depression, or characterization of intersects between genetic mechanisms associated with depression and other known risk factors (as identified in published literature) for development of PD. · Identification of surrogate markers in the blood for identification, diagnosis, susceptibility, maintenance, or progression of depression associated with neurodegeneration. Innovative applications not focused on the Areas of Emphasis noted above are acceptable, provided the application: · Is specifically related to development or progression of depression as a non-motor manifestation of PD and/or is clearly linked to depression as a risk factor for initiation or progression of PD; and · Provides a strong rationale for relevance to the mission of the NETPR Program. The Depression Research Award mechanism is being offered for the first time in FY15. The intent of the NETPR Depression Research Award is to support research efforts that will make significant advancements in the understanding of serotonergic and non-serotonergic molecular pathways identified with depression and associated biologic phenomena that link the pathways to other risk factors (e.g., disruption of sleep architecture, exposure to long-term psychological and physiological stress, dysautonomia, and traumatic brain injury) for development and progression of PD. It is expected that research supported by this award will lead to the development of new treatments or the improvement of current treatments for depression, specifically in individuals with, or at risk for, PD. It is anticipated that projects will emphasize preclinical research in human populations, animal studies, or in silico retrospective studies. Preliminary data are required.



Please enter your comment!
Please enter your name here